In terms of blood lipid levels (Fig. 6E), compared with the NAFLD + DMSO group, AMPK-IN-3 treatment increased the levels of TG and LDL-C, while decreasing HDL-C (P < 0.001). This evidence concerns the gene PRKAA1 and metabolic dysfunction-associated steatotic liver disease.